Entera Bio Ltd. (ENTX)
Largest Insider Buys in Sector
ENTX Stock Price History Chart
ENTX Stock Performance
About Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license …
Insider Activity of Entera Bio Ltd.
Over the last 12 months, insiders at Entera Bio Ltd. have bought $15,269 and sold $0 worth of Entera Bio Ltd. stock.
On average, over the past 5 years, insiders at Entera Bio Ltd. have bought $92,621 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Taitel Haya (director) — $15,269.
The last purchase of 9,500 shares for transaction amount of $9,405 was made by Taitel Haya (director) on 2024‑01‑12.
List of Insider Buy and Sell Transactions, Entera Bio Ltd.
| 2024-01-12 | director | 9,500 0.0311% | $0.99 | $9,405 | +69.78% | |||
| 2024-01-10 | director | 7,615 0.0264% | $0.77 | $5,864 | +133.77% | |||
| 2023-12-22 | director | 23,952 0.0901% | $0.71 | $17,006 | +169.70% | |||
| 2023-12-22 | Chief Executive Officer | 23,952 0.0901% | $0.71 | $17,006 | +169.70% | |||
| 2023-08-22 | director | 18,000 0.0572% | $0.62 | $11,216 | +43.74% | |||
| 2023-08-21 | director | 20,000 0.0715% | $0.59 | $11,784 | +56.62% | |||
| 2023-08-21 | director | 40,000 0.1456% | $0.60 | $24,000 | +56.62% | |||
| 2023-04-04 | Chief Executive Officer | 30,000 0.1073% | $1.01 | $30,300 | -18.72% | |||
| 2022-11-14 | director | 38,000 0.1348% | $0.57 | $21,740 | +44.64% | |||
| 2022-11-14 | Chief Financial Officer | 26,580 0.0883% | $0.54 | $14,247 | +44.64% | |||
| 2022-11-11 | director | 30,000 0.1104% | $0.53 | $15,900 | +62.00% | |||
| 2022-11-11 | Chief Executive Officer | 50,000 0.1846% | $0.53 | $26,585 | +62.00% | |||
| 2022-11-11 | Chief Financial Officer | 30,000 0.1083% | $0.52 | $15,600 | +62.00% | |||
| 2022-07-21 | 19,491 0.0602% | $1.68 | $32,803 | -52.59% | ||||
| 2022-07-21 | 14,900 0.0448% | $1.64 | $24,406 | -52.59% |
Insider Historical Profitability
| Taitel Haya | director | 35115 0.0953% | $2.18 | 3 | 0 | |
| LIEBERMAN GERALD M | director | 226961 0.6162% | $2.18 | 4 | 0 | <0.0001% |
| Toledano Miranda Jayne | Chief Executive Officer | 110752 0.3007% | $2.18 | 3 | 0 | +21.64% |
| Ellis Sean | director | 102100 0.2772% | $2.18 | 3 | 0 | +4.7% |
| Yaacov-Garbeli Dana | Chief Financial Officer | 56580 0.1536% | $2.18 | 2 | 0 | +53.32% |